Gross Profit Summary of Evotec SE

Evotec SE's latest annual gross profit in 2023 was 175.05 Million EUR , up 0.57% from previous year.
Evotec SE's latest quarterly gross profit in 2024 Q2 was 15.74 Million EUR , down -54.71% from previous quarter.
Evotec SE reported a annual gross profit of 174.06 Million EUR in annual gross profit 2022, up 14.86% from previous year.
Evotec SE reported a annual gross profit of 151.54 Million EUR in annual gross profit 2021, up 20.52% from previous year.
Evotec SE reported a quarterly gross profit of 34.75 Million EUR for 2024 Q1, down -7.72% from previous quarter.
Evotec SE reported a quarterly gross profit of 46.32 Million EUR for 2023 Q2, down -12.99% from previous quarter.

Annual Gross Profit Chart of Evotec SE (2023 - 2001)

Historical Annual Gross Profit of Evotec SE (2023 - 2001)

Year	Gross Profit	Gross Profit Growth
2023	175.05 Million EUR	0.57%
2022	174.06 Million EUR	14.86%
2021	151.54 Million EUR	20.52%
2020	125.74 Million EUR	-5.38%
2019	132.89 Million EUR	18.64%
2018	112.01 Million EUR	35.67%
2017	82.56 Million EUR	41.01%
2016	58.55 Million EUR	54.14%
2015	37.98 Million EUR	29.3%
2014	29.37 Million EUR	-5.91%
2013	31.22 Million EUR	0.64%
2012	31.02 Million EUR	-11.32%
2011	34.98 Million EUR	43.7%
2010	24.34 Million EUR	32.16%
2009	18.42 Million EUR	4.45%
2008	17.63 Million EUR	119.82%
2007	8.02 Million EUR	-65.04%
2006	22.95 Million EUR	8.63%
2005	21.12 Million EUR	991.09%
2004	1.93 Million EUR	-45.81%
2003	3.57 Million EUR	0.0%
2002	- EUR	0.0%
2001	- EUR	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	15.74 Million EUR	-54.71%
2024 Q1	34.75 Million EUR	-7.72%
2023 Q2	46.32 Million EUR	-12.99%
2023 Q4	37.66 Million EUR	-0.42%
2023 Q1	53.23 Million EUR	-35.44%
2023 Q3	37.82 Million EUR	-18.35%
2023 FY	175.05 Million EUR	0.57%
2022 FY	174.06 Million EUR	14.86%
2022 Q1	32.29 Million EUR	-37.98%
2022 Q2	30.89 Million EUR	-4.33%
2022 Q3	28.42 Million EUR	-8.01%
2022 Q4	82.45 Million EUR	190.13%
2021 FY	151.54 Million EUR	20.52%
2021 Q3	43.16 Million EUR	68.47%
2021 Q4	52.07 Million EUR	20.63%
2021 Q2	25.62 Million EUR	-16.48%
2021 Q1	30.67 Million EUR	-16.07%
2020 Q2	19.79 Million EUR	-40.51%
2020 FY	125.74 Million EUR	-5.38%
2020 Q4	36.55 Million EUR	1.19%
2020 Q1	33.27 Million EUR	-2.38%
2020 Q3	36.12 Million EUR	82.51%
2019 Q2	32.14 Million EUR	1.56%
2019 FY	132.89 Million EUR	18.64%
2019 Q1	31.65 Million EUR	11.75%
2019 Q3	35 Million EUR	8.9%
2019 Q4	34.08 Million EUR	-2.65%
2018 Q1	18.48 Million EUR	-17.9%
2018 Q3	33.4 Million EUR	5.02%
2018 Q2	31.8 Million EUR	72.03%
2018 FY	112.01 Million EUR	35.67%
2018 Q4	28.32 Million EUR	-15.2%
2017 Q4	22.51 Million EUR	-2.24%
2017 Q1	18.78 Million EUR	54.44%
2017 Q2	18.23 Million EUR	-2.93%
2017 Q3	23.03 Million EUR	26.36%
2017 FY	82.56 Million EUR	41.01%
2016 Q3	20.38 Million EUR	50.66%
2016 Q2	13.53 Million EUR	8.52%
2016 Q1	12.47 Million EUR	5.53%
2016 Q4	12.16 Million EUR	-40.36%
2016 FY	58.55 Million EUR	54.14%
2015 Q4	11.81 Million EUR	13.6%
2015 Q3	10.4 Million EUR	13.78%
2015 Q2	9.14 Million EUR	38.05%
2015 Q1	6.62 Million EUR	-47.9%
2015 FY	37.98 Million EUR	29.3%
2014 FY	29.37 Million EUR	-5.91%
2014 Q2	7.17 Million EUR	55.6%
2014 Q4	12.71 Million EUR	160.76%
2014 Q3	4.87 Million EUR	-32.08%
2014 Q1	4.61 Million EUR	-51.87%
2013 Q1	4.45 Million EUR	-41.62%
2013 FY	31.22 Million EUR	0.64%
2013 Q4	9.58 Million EUR	-13.56%
2013 Q3	11.08 Million EUR	81.78%
2013 Q2	6.09 Million EUR	36.96%
2012 Q4	7.62 Million EUR	-11.4%
2012 Q2	8.25 Million EUR	26.46%
2012 Q3	8.6 Million EUR	4.24%
2012 FY	31.02 Million EUR	-11.32%
2012 Q1	6.53 Million EUR	6.91%
2011 Q2	8.49 Million EUR	42.7%
2011 Q1	5.95 Million EUR	-18.09%
2011 FY	34.98 Million EUR	43.7%
2011 Q4	6.1 Million EUR	-57.68%
2011 Q3	14.43 Million EUR	69.97%
2010 Q4	7.26 Million EUR	24.68%
2010 Q1	3.72 Million EUR	-48.71%
2010 Q2	7.52 Million EUR	101.8%
2010 Q3	5.82 Million EUR	-22.56%
2010 FY	24.34 Million EUR	32.16%
2009 FY	18.42 Million EUR	4.45%
2009 Q1	2.97 Million EUR	-63.04%
2009 Q2	4.07 Million EUR	36.82%
2009 Q3	4.09 Million EUR	0.47%
2009 Q4	7.27 Million EUR	77.56%
2008 Q3	5.92 Million EUR	294.99%
2008 Q4	8.05 Million EUR	35.99%
2008 Q2	1.5 Million EUR	-30.28%
2008 Q1	2.15 Million EUR	-36.73%
2008 FY	17.63 Million EUR	119.82%
2007 Q1	- EUR	-100.0%
2007 FY	8.02 Million EUR	-65.04%
2007 Q2	7.56 Million EUR	0.0%
2007 Q4	3.4 Million EUR	137.12%
2007 Q3	1.43 Million EUR	-81.03%
2006 FY	22.95 Million EUR	8.63%
2006 Q3	1.69 Million EUR	-40.69%
2006 Q4	34.05 Million EUR	1910.04%
2006 Q1	2.04 Million EUR	-10.53%
2006 Q2	2.85 Million EUR	39.72%
2005 Q3	- EUR	-100.0%
2005 Q4	2.28 Million EUR	0.0%
2005 Q1	506.05 Thousand EUR	43.37%
2005 Q2	541.81 Thousand EUR	7.06%
2005 FY	21.12 Million EUR	991.09%
2004 FY	1.93 Million EUR	-45.81%
2004 Q3	- EUR	-100.0%
2004 Q1	532.44 Thousand EUR	285.4%
2004 Q2	537.81 Thousand EUR	1.01%
2004 Q4	352.97 Thousand EUR	0.0%
2003 Q4	-287.19 Thousand EUR	0.0%
2003 Q2	- EUR	0.0%
2003 FY	3.57 Million EUR	0.0%
2003 Q1	- EUR	0.0%
2003 Q3	- EUR	0.0%
2002 FY	- EUR	0.0%
2001 FY	- EUR	0.0%

Peer Gross Profit Comparison of Evotec SE

Name	Gross Profit	Gross Profit Difference
MPH Health Care AG	180.33 Million EUR	2.928%
Apontis Pharma AG	-3.33 Million EUR	5347.01%
Dermapharm Holding SE	342.86 Million EUR	48.944%
MERCK Kommanditgesellschaft auf Aktien	11.66 Billion EUR	98.5%
PharmaSGP Holding SE	91.63 Million EUR	-91.027%
SynBiotic SE	1.5 Million EUR	-11520.347%

Global Stocks Search

Evotec SE (EVT.DE)

Gross Profit Summary of Evotec SE

Annual Gross Profit Chart of Evotec SE (2023 - 2001)

Historical Annual Gross Profit of Evotec SE (2023 - 2001)

Peer Gross Profit Comparison of Evotec SE